Most people comparing TMS vs medication for depression arrive at the question the same way: the antidepressants have not brought enough relief. If that is you, it helps to know that both are evidence-based, FDA-cleared treatments, and they work in completely different ways. Medication adjusts brain chemistry from the inside. TMS stimulates the brain directly with magnetic pulses. Neither is universally better. The right choice depends on your treatment history, the severity of your symptoms, how you tolerate side effects, and your own preferences, especially once you are dealing with treatment-resistant depression or trying to figure out what to do when antidepressants don't work. This article compares the two fairly, not to push one over the other.
How Antidepressants Work
Antidepressants change the availability of certain brain chemicals, mainly serotonin and norepinephrine, that influence mood. The most common are SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors). Both are considered first-line treatment, meaning they are usually where a clinician starts.
They are taken daily as a pill at home, and they work gradually. Most people need several weeks before the full effect shows, which is one of the harder parts of starting an antidepressant: you often have to wait to know whether it is working. Finding the right medication and dose regularly takes some trial and adjustment, and a first medication that does not help does not mean none will. There are many options within each class, so a clinician can switch or fine-tune based on how a person responds. Older tricyclic antidepressants (TCAs) also work but tend to cause harsher side effects, so they are usually reserved for later steps rather than first-line use. The main appeal of medication is convenience and evidence: it is taken at home, it is inexpensive, and it has decades of research behind it.
How TMS Works
Transcranial magnetic stimulation (TMS) is a non-invasive treatment that uses focused magnetic pulses, similar in strength to an MRI, to stimulate the mood-regulating areas of the brain that tend to be underactive in depression, mainly the left dorsolateral prefrontal cortex. It is FDA-cleared for major depressive disorder in adults, and also for OCD (NIMH, Brain Stimulation Therapies).
TMS is not electroconvulsive therapy (ECT). There is no anesthesia and no sedation, and the patient stays fully awake through each session, then drives home and returns to normal activity. During a session, a coil rests against the scalp and delivers pulses in short cycles, which most people feel as a tapping sensation. A typical course runs about five days a week for several weeks, with each session lasting under an hour, and the benefit tends to build gradually across the course rather than after any single visit.
As a non-drug option, TMS is one of the main alternatives to antidepressants for people whose medication has stopped short. It usually works best as part of a broader treatment plan, coordinated with therapy and, in many cases, ongoing medication, rather than as a replacement for all other care.
TMS vs Medication: Side-by-Side Comparison
The two treatments differ on almost every practical dimension, from how they are delivered to how quickly they work and what they ask of you day to day. The table below lays the key differences side by side, and the sections that follow unpack the two that matter most to people making this decision: side effects and success rates.
Side Effects Compared
Antidepressant side effects vary by class. SSRIs commonly cause weight gain and sexual dysfunction, though some effects ease after the first few weeks. SNRIs have a similar profile that is often milder. TCAs tend to be harsher, which is why they are rarely a first choice. These are systemic effects, because the medication acts throughout the body.
TMS side effects are usually mild and short-lived: scalp discomfort, headache, or lightheadedness that typically passes soon after a session and lessens over the first week. The most serious risk, seizure, is very rare. Because TMS is non-invasive and targeted rather than systemic, it avoids the weight, sexual, and sleep side effects associated with medication, and it does not affect memory or cognition the way some people fear based on older brain treatments like ECT.
It is not side-effect-free, though, and its main practical downside is different in kind. Instead of a daily side effect, TMS asks for a time commitment: traveling to a clinic most weekdays for several weeks. For someone with a demanding schedule or limited transportation, that logistical cost is real and worth weighing against the appeal of avoiding medication side effects. Neither profile is automatically easier to live with; they are simply different, and which one fits depends on the person.
Success Rates: What the Research Shows
Both treatments help many people, and neither helps everyone. Reading the numbers honestly matters more than cheerleading for either one. Two terms come up often: response means a meaningful reduction in symptoms, usually cutting them roughly in half, while remission means symptoms largely resolve. Remission is the higher bar and the real goal.
For medication, the landmark STAR*D study found that roughly a third of patients reached remission on their first SSRI (Trivedi et al., American Journal of Psychiatry, 2006). That is a genuinely useful result for many people. But it also means most did not remit on the first try, and STAR*D showed that with each additional medication tried after a failure, the odds of remission tend to drop while side-effect burden tends to rise. That diminishing return is exactly the situation that leads people to look at other options.
For TMS, a large real-world registry of more than 5,000 patients found that most experienced measurable improvement, with response rates ranging from about 58% to 83% and remission from about 28% to 62%, depending on how outcomes were measured (Sackeim et al., Journal of Affective Disorders, 2020). The wide ranges are worth noting: they reflect different rating scales and patient groups, and many of those patients were also taking medication, so the numbers describe TMS in real-world use rather than in isolation.
For treatment-resistant depression specifically, a 2024 randomized trial compared TMS with switching or augmenting medication in 89 people who had not responded to at least two antidepressants, with both groups also receiving psychotherapy. The TMS group had significantly higher response and remission rates than the medication group (Dalhuisen et al., American Journal of Psychiatry, 2024). It is one of the clearest head-to-head comparisons available, though individual results always vary, and these figures describe groups, not guarantees for any one person.
When Antidepressants Don't Work: Where TMS Fits
About a third of people with major depressive disorder do not respond adequately to first-line treatment, a pattern clinicians call treatment-resistant depression. It is not a sign of personal failure or a rare edge case; it is common, and it has its own growing set of treatment options. When two or more medications have failed, or when side effects are intolerable, TMS becomes a well-supported next step, and the 2024 trial above is part of why it is increasingly positioned early in the treatment-resistant pathway rather than as a last resort.
TMS is not the only option at this stage. Spravato (esketamine), a nasal spray derived from ketamine, is FDA-approved for treatment-resistant depression when used together with an oral antidepressant. It is given in a certified clinic under medical supervision, with monitoring after each dose, because of its dissociative effects. Combining TMS with an antidepressant is another route, and research suggests the combination can improve outcomes over medication alone. The larger point is that once first-line medication falls short, the path forward branches into several evidence-based options, and those branches are not mutually exclusive. A person might use medication and TMS together, or move from one approach to another as their psychiatrist learns what their brain responds to.
Who Is Each Treatment For?
Medication is often the right starting point for someone who is:
- Early in treatment for depression
- Managing mild to moderate symptoms
- Looking to avoid in-clinic visits
- Someone who has responded well to an antidepressant before
TMS is generally considered for someone who:
- Has tried multiple antidepressants without adequate relief
- Cannot tolerate medication side effects
- Prefers a non-drug approach
- Has treatment-resistant depression
Many people use both at different points, and some use them together. Where a person lands is a clinical decision, not a solo consumer choice, and it belongs with a psychiatrist who knows the full history.
Making the Decision With a Psychiatrist
TMS, medication, Spravato, and therapy are not competing products. They are tools a psychiatrist combines and adjusts based on diagnosis, history, and how a person responds over time. Comparing TMS and medication on paper is useful, but the decision is rarely either-or, and it is rarely one-and-done. It usually looks more like a sequence: start somewhere reasonable, measure the response, and adjust. The most reliable way to navigate that sequence, and to change course when needed, is a thorough evaluation within an integrated care setting, where the clinician managing your medication is the same one weighing whether TMS or another option fits.
That is how care works at Amae Health. Our psychiatry-led teams evaluate the whole picture and coordinate treatment across medication, therapy, and procedures like TMS, which we offer at our Los Angeles clinic. You can explore our full range of treatments or, for severe depression that needs more structure, our Partial Hospitalization Program. Our resources for patients and families explain how integrated care works, and you can contact our team to ask about an evaluation.
Frequently Asked Questions
Is TMS better than medication for depression? Neither is universally better. Medication is first-line and works well for many people. For treatment-resistant depression, where two or more medications have failed, TMS often outperforms a medication switch. The right choice depends on history, severity, and side-effect tolerance.
Can you do TMS and take antidepressants at the same time? Yes. TMS can be combined with antidepressants, and research suggests the combination can improve outcomes compared with medication alone. This should be coordinated by a psychiatrist.
What are the side effects of TMS vs medication? TMS side effects are usually mild and short-lived, mainly scalp discomfort or headache that fades after the first week. Medication side effects vary but can include weight change, sexual dysfunction, and fatigue. Because it is non-invasive, TMS avoids the systemic side effects of medication.
Does TMS work when antidepressants don't? Often, yes. TMS is specifically supported for treatment-resistant depression. A 2024 randomized trial found higher response and remission rates with TMS than with switching medications after failed trials. Individual results vary.
How long does TMS treatment take? A typical course is sessions about five days a week for several weeks, each lasting under an hour. Antidepressants, by contrast, are taken daily and may take several weeks to show their full effect.
What if neither TMS nor medication works? Other options exist, including Spravato (esketamine) used with an oral antidepressant, combination approaches, and structured programs like IOP or PHP for severe depression. A psychiatrist can help identify next steps. Depression is hard, and support is available: if you are struggling, call or text the 988 Suicide and Crisis Lifeline at 988, anytime.
Citations
- Trivedi MH, Rush AJ, Wisniewski SR, et al. "Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D." American Journal of Psychiatry, 2006. psychiatryonline.org. Tier 1 (peer-reviewed).
- Sackeim HA, Aaronson ST, Carpenter LL, et al. "Clinical outcomes in a large registry of patients with major depressive disorder treated with transcranial magnetic stimulation." Journal of Affective Disorders, 2020. sciencedirect.com. Tier 1 (peer-reviewed).
- Dalhuisen I, van Oostrom I, Spijker J, et al. "rTMS as a Next Step in Antidepressant Nonresponders: A Randomized Comparison With Current Antidepressant Treatment Approaches." American Journal of Psychiatry, 2024. PubMed 39108161. Tier 1 (peer-reviewed RCT).
- National Institute of Mental Health, "Brain Stimulation Therapies." nimh.nih.gov. Tier 2 (U.S. government).
Further reading (external resources): NIMH, Depression; Mayo Clinic, Transcranial Magnetic Stimulation.
